European Investment Bank
VC Fund
Luxembourg, Luxembourg
European Investment Bank is a VC fund in Luxembourg focused on Biotechnology and Energy. The European Investment Bank (EIB) offers lending, borrowing, and treasury services primarily within the European Union. It provides project loans for public and private sectors, loans to banks and intermediaries, structured finance products, guarantees, and securitization instruments for debts. Additionally, EIB offers equity and fund investmentproducts, including infrastructure and environmental funds, as well as venture capital funds. EIB also supports microfinance and risk-sharing finance for research and innovation, and provides technical expertise for sustainable energy projects. Its services include infrastructure advisory, urban development support, guarantees for transport infrastructure, and funding for public-private partnerships and small- to medium-sized enterprises. The bank serves various sectors, including transportation, energy, health, education, and agriculture.
- Total investments:
- 595
- Last investment:
- Lead investor:
- 83%
Last updated:
For AI agents: llms.txt
Industries European Investment Bank invests in
Stages European Investment Bank invests in
Countries European Investment Bank invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 17 contacts → | |||
Round size
- Post-IPO Debt
- $18M–$587M
- Debt Financing
- $16M–$355M
- Venture - Series Unknown
- $8.7M–$90M
Investment Focus
Industry
- Biotechnology 78 (13%)
- Energy 77 (13%)
- Health Care 67 (11%)
- Renewable Energy 61 (10%)
- Manufacturing 60 (10%)
Stage
- Debt Financing 325 (55%)
- Post-IPO Debt 122 (21%)
- Venture - Series Unknown 23 (4%)
- Grant 11 (2%)
- Series B 9 (2%)
Country
- France 58 (10%)
- Germany 56 (9%)
- Spain 45 (8%)
- Italy 44 (7%)
- The Netherlands 30 (5%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Gelsomina Vigliotti
Vice President
|
Vice President | Total investments: 11 | Find email | |
Myriam Rouis
Senior Investment Manager/Advisor - EIC Fund - Venture Capital
|
Senior Investment Manager/Advisor - EIC Fund - Venture Capital | Total investments: 1 | Find email | |
Ambroise Fayolle
Vice-President
|
Vice-President | Total investments: 45 | Find email | |
|
Andrus Ansip
Vice President
|
Vice President | Total investments: 0 | Find email | |
Edward Claessen
Head of Non-EU Infrastructure & Climate Funds
|
Head of Non-EU Infrastructure & Climate Funds | Total investments: 0 | Find email | |
| See all 17 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| VaxThera develops and produces vaccines to prevents and treats diseases. | $39.8M / Debt Financing / Sep 24, 2026 | ||
| Reactive Technologies we are committed to enabling a more intelligent use of energy, for the largest and most complex business to the smallest household. Our aim is to develop new technologies that will positively assist the energy industry to deliver cleaner, greener and more affordable energy, through more efficient and effective energymanagement and control. Through our innovative, cloud-based solution for Corporate customers – Tradenergy® – we have begun this process and with our pipeline of ground breaking new technologies we intend to continue. | $21.7M / Debt Financing / Sep 23, 2026 | ||
| HighLife is a company focused on Transcatheter Mitral Valve Replacement (TMVR). The technology is intended for treatment of patients suffering from mitral valve regurgitation and is currently in a stage of clinical evaluation.The company was co-founded in 2010 by Mr. Georg Börtlein, President & CEO. The intent is to provide a minimallyinvasive prosthetic mitral valve that is implanted on a beating heart, while preserving the native valve structure and respecting the surrounding anatomy. Ease and safety of use and delivery are key elements of the HighLife technology. | $90M / Venture - Series Unknown / Sep 22, 2026 | ||
| Morphotonics develops and sells nano and micro imprint structures as well as designs nanoimprint machine and supplies it. | $45.9M / Series B / Sep 22, 2026 | ||
| EcoGraf is building a vertically integrated business to produce high purity graphite for the lithium-ion battery market. | $2.3M / Grant / Sep 21, 2026 | ||
| We believe that all patients deserve the most innovative, open surgical treatment options so they can live their fullest lives. We’re on a mission to advance robotic technology that pushes the limits of soft tissue open surgery and opens new opportunities for surgeons to restore quality of life for more patients with complex conditions. TheSymani® Surgical System is a first-of-its kind robotic technology that uniquely addresses the scale and complexities of microsurgery and supermicrosurgery to restore quality of life for more patients. | $19.6M / Venture - Series Unknown / Sep 16, 2026 | ||
| Skyborn Renewables develops, builds, and operates offshore wind projects across the full lifecycle. The company identifies sites, secures permits, structures financing, and manages engineering, procurement, and construction. Its teams plan grid connections and deliver operations and maintenance for utility-scale assets. Skyborn Renewables alsoprovides asset management, health and safety oversight, and environmental monitoring throughout project life. Services include offtake strategy and power sales support, stakeholder engagement, and supply chain coordination. The portfolio covers greenfield development, joint ventures, and acquisitions, with capabilities from early-stage studies to long-term operation. Technology work spans turbine selection, foundation design, cable layout, and digital performance analytics. Skyborn Renewables collaborates with partners to expand renewable generation and enable electrification through offshore wind energy. | $2.4B / Debt Financing / Sep 11, 2026 | ||
| ETHRIS develops mRNA therapeutics with a focus on respiratory diseases and vaccines. ETHRIS possesses an enabling LNP delivery and mRNA modification platform for transcript Therapies. SNIM®RNAis a first-in-class biopharmaceutical which provide a compelling alternative for recombinant protein or gene therapies. SNIM®RNAs encode therapeutic proteinsto be produced in the patient‘s body and overcome short duration effects of recombinant proteins. SNIM®RNA Transcript Therapy is a new option for a broad variety of diseases, either acquired or genetically predetermined, lifestyle- or age-related, rare or frequent. | $34.9M / Debt Financing / Sep 10, 2026 | ||
| TeamViewer focuses on cloud-based technologies to enable online remote support and collaboration globally. The company proactively shapes digital transformation and continuously innovates in Augmented Reality, Internet of Things, and Artificial Intelligence. TeamViewer is at the forefront of that innovation. It should act as a catalyst to promoteand amplify people’s ideas and their ability to solve issues and overcome challenges. | $191.8M / Post-IPO Debt / Sep 08, 2026 | ||
| Elia is a builder and operator of the high-voltage transmission system operator. Elia was founded in 2001 and was headquartered in Brussels, Belgium. | $1.2B / Debt Financing / Sep 07, 2026 | ||
| See all 595 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does European Investment Bank invest in?
European Investment Bank invests primarily in Biotechnology, Energy and Health Care startups, most often at Debt Financing and Post-IPO Debt stage. Most of the 595 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is European Investment Bank's check size?
European Investment Bank typically joins rounds of $18M–$587M at Post-IPO Debt, $16M–$355M at Debt Financing and $8.7M–$90M at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds European Investment Bank participates in.
How do I contact European Investment Bank?
Public channels for European Investment Bank include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at European Investment Bank?
The team at European Investment Bank includes Gelsomina Vigliotti (Vice President), Myriam Rouis (Senior Investment Manager/Advisor - EIC Fund - Venture Capital) and Ambroise Fayolle (Vice-President), among 17 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
